<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Seventeen children with advanced <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> (induction failure, relapse, <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>, <z:e sem="disease" ids="C0280449" disease_type="Neoplastic Process" abbrv="">secondary AML</z:e>, or CR &gt;1) received thiotepa 750 mg/m2 i.v., <z:chebi fb="0" ids="28901">busulfan</z:chebi> 12 mg/kg or 640 mg/m2 p.o., and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> 120 mg/kg i.v. as a preparative regimen for allogeneic or autologous hematopoietic stem cell (<z:chebi fb="15" ids="50443">HSC</z:chebi>) transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>Of the 15 allogeneic transplants, eight were from matched siblings, one was from a mismatched sibling, and six were from unrelated donors </plain></SENT>
<SENT sid="2" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis consisted of <z:chebi fb="0" ids="4031">cyclosporine</z:chebi> or tacrolimus and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain>Regimen-related toxicity was common but tolerable, affecting mainly the skin and gastrointestinal tract </plain></SENT>
<SENT sid="4" pm="."><plain>Three patients died early and were not evaluable for engraftment; engraftment occurred in the remaining patients </plain></SENT>
<SENT sid="5" pm="."><plain>Nine patients with active disease at the time of transplant were evaluable for response; <z:hpo ids='HP_0000001'>all</z:hpo> achieved remission </plain></SENT>
<SENT sid="6" pm="."><plain>With a median follow-up of 40 months (range, 10-71 months), nine patients are alive and disease-free </plain></SENT>
<SENT sid="7" pm="."><plain>The 3-year actuarial event-free survival was 51% (95% confidence interval (CI) 27-76%) </plain></SENT>
<SENT sid="8" pm="."><plain>Seven patients died of transplant-related complications: <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> (n = 4), <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (n = 1), <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">VOD</z:e>, (n= 1) and <z:mp ids='MP_0010909'>pulmonary alveolar hemorrhage</z:mp> (n = 1) </plain></SENT>
<SENT sid="9" pm="."><plain>Only one patient had <z:hpo ids='HP_0001909'>leukemia</z:hpo> relapse and died </plain></SENT>
<SENT sid="10" pm="."><plain>We conclude that the use of high-dose thiotepa, <z:chebi fb="0" ids="28901">busulfan</z:chebi> and <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> is an effective conditioning regimen for childhood <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> and may be tested in patients with less advanced disease (eg CR1) </plain></SENT>
</text></document>